Trifecta Multimedical, a global provider of online clinical investigator training, introduced InvestigatorSpace.com, designed to give clinical trial sponsors and sites unprecedented capabilities for clinical training and site operations.
InvestigatorSpace.com streamlines clinical trial site management and oversight without compromising quality or compliance. It is a web-based application that tracks, validates and reports investigator training activity through one simple interface, regardless of how training is conducted.
“We set out to empower investigators in entirely new ways. At the same time, we wanted to provide sponsors with a level of tracking and validation that has simply never been available before,” says Trifecta Multimedical CEO Dave Young.
InvestigatorSpace.com unifies training and collaboration done on-line, at in-person investigator meetings, web conferences and using off-the-shelf solutions provided by competitors.
“InvestigatorSpace.com lets investigators make their own decisions in a controlled manner, taking a huge administrative burden off study teams,” says Young. “It dovetails perfectly with sponsors’ training plans. It’s like the difference between driving a stick shift and an automatic. There are so many steps that are now completely automated.”
InvestigatorSpace.com has been in development for the past two years. During that time, Trifecta continually interviewed sites, sponsors and clinical research organizations regarding training challenges and opportunities to improve site operations. “We wanted to find all the gaps and close them,” says Young. The company expects InvestigatorSpace.com to elevate sponsors’ expectations of training technologies. Young calls it “raising the industry IQ.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.